Vestikap, 24 mg capsules 30 pcs

Vestigap is a synthetic analog of histamine. Betahistine acts mainly on histamine H1 and H3-receptors of the inner ear and vestibular nuclei of the CNS.

By direct agonist action on the H1-receptors of the inner ear vessels and also indirectly on the H3-histamine receptors of the CNS vestibular nuclei; it improves microcirculation and capillary permeability, normalizes the endolymph pressure in the labyrinth and cochlea.

At the same time, betahistine increases blood flow in the basilar artery. It accelerates recovery of vestibular function after unilateral vestibular neurectomy, accelerating and facilitating central vestibular compensation (due to antagonism with H3-histamine receptors). It has a pronounced central effect, being an inhibitor of H3-receptor nuclei of the vestibular nerve. It dose-dependently reduces the generation of action potentials in the neurons of the lateral and medial vestibular nuclei.

It relieves symptoms of Meniere’s syndrome and vestibular vertigo. Stable therapeutic effect occurs after 14 days.

Pharmacokinetics

Absorption and distribution

After oral administration betahistine is rapidly absorbed; binding to plasma proteins is low. Time to reach Cmax in plasma is 3 hours.

Metabolism and excretion

Metabolized to inactive metabolites: 2-pyridylacetic acid (main metabolite) and demethylbetahistine.

85-90% is excreted by the kidneys as 2-pyridylacetic acid within 24 hours. Excretion of betahistine and demethylbetahistine by the kidneys is insignificant. Only a small portion of betahistine and its metabolites are excreted through the intestine.

Indications

Treatment of Meniere’s syndrome characterized by vertigo (accompanied by nausea and vomiting), hearing loss and tinnitus; symptomatic treatment of vestibular vertigo (vertigo).

Active ingredient

Composition

1 capsule contains:

Active substance:

Betahistine dihydrochloride 24 mg;

Associates:

Lactose monohydrate (milk sugar);

Microcrystalline cellulose;

Potato starch;

copovidone;

sodium carboxymethyl starch;

colloidal silicon dioxide;

Magnesium stearate.

How to take, the dosage

Overly, with meals.

The single dose of Vestikap is 8-16 mg, the frequency of administration is 3 times a day.

At the beginning of therapy, improvement is usually seen; stable therapeutic effect occurs after two weeks of treatment and may increase over several months of treatment. The treatment is long. The duration of therapy is determined individually.

Interaction

There are currently no data on drug interactions of betahistine.

Special Instructions

Therapeutic effect in a number of cases builds up within a few months of the start of treatment.

Impact on driving and operating machinery

Betahistine has no sedative effect and does not affect the ability to drive or engage in activities requiring rapid psychomotor reactions.

Contraindications

With caution: peptic ulcer or duodenal ulcer (including history), pheochromocytoma, bronchial asthma. Patients in these groups should be monitored regularly during treatment.

Side effects

Digestive system disorders: nausea, vomiting, abdominal pain, abdominal distension, dyspepsia.

Skin disorders: angioedema, urticaria, itching, rash.

Allergic reactions: hypersensitivity, including anaphylactic reactions.

Overdose

Symptoms: nausea, abdominal pain, drowsiness (when taken in doses up to 640 mg); seizures, cardiovascular complications (when taken in doses greater than 640 mg or in combination with other drugs).

Treatment: symptomatic.

Similarities